

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI XDC CAYMAN INC.

藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2268)

VOLUNTARY ANNOUNCEMENT

IN RELATION TO BUSINESS UPDATE OF WUXI BIOLOGICS

This announcement is made by WuXi XDC Cayman Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of WuXi Biologics (Cayman) Inc. (“**WuXi Biologics**”, together with its subsidiaries, the “**WuXi Biologics Group**”) dated December 4, 2023 in relation to the 2023 business update of WuXi Biologics Group.

On December 4, 2023, WuXi Biologics, being the Company’s parent company, convened a business update meeting and conducted a presentation containing financial and other information regarding WuXi Biologics Group (the “**Presentation**”), which includes certain forward-looking statements related to the 2023 and 2024 expected performance of the Company. Shareholders and potential investors of the Company are reminded that such forward-looking statements are, by their nature, subject to significant uncertainties, and therefore, undue reliance should not be placed on them.

The Company would also like to emphasize that the Group’s business operation has progressed as planned, and that there has been no adverse change to its business operation. The Company has full confidence in the prospects of its future development and currently is not aware of any factors which may significantly affect its business plan or growth target.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincai Li
Executive Director and Chief Executive Officer

Hong Kong, December 4, 2023

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincai LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Weichang ZHOU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Stewart John HEN and Mr. Hao ZHOU as independent non-executive directors.

* *For identification purpose only*